Please turn JavaScript on
PM361 icon

PM361

Subscribe in seconds and receive PM361's news feed updates in your inbox, on your phone or even read them from your own news page here on follow.it.

You can select the updates using tags or topics and you can add as many websites to your feed as you like.

And the service is entirely free!

Follow PM361: PM360 - The Essential Resource for Pharma Marketers

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.4 / day

Message History

Former Google and Klick Healthcare Executive Joins MDCalc  Hire Signals Growth for Trusted Information Provider to Millions of Physicians New York, NY  September 2, 2026 – MDCalc, the physician-owned clinical decision support platform used by millions of healthcare professionals annually to assess their patients, today announced Ryan Olohan as Head of Sales,...

Read full story

Internationally respected policy leader and convener strengthens agency’s ability to advise life sciences companies, foundations and nongovernmental organizations on the complex issues shaping global health and innovation access

Wednesday, September 2nd – NEW YORK and LONDON — FINN Partners, one of the world’s largestindepende...


Read full story
On Thursday, August 27, EVERSANA and Google Cloud hosted more than 80 leaders from pharmaceutical brands in New York to showcase what’s new on teh company’s AI Agency Platform, and where the companies will focus on next – broader commercialization services powered by AI. Speakers included CEO Mark Thierer, Chief Innovation Officer Faruk Capan, President, Patient Services Brian ...

Read full story

Collaboration expands deployment of EVERSANA’s AI Agency platform and commercialization capabilities to advance Lundbeck’s Focused Innovator strategy and bionic ambitions 

CHICAGO and DEERFIELD, Ill. – August 25, 2026Lundbeck, a global pharmaceutical company focused e...


Read full story

Merck and Moderna’s investigational mRNA vaccine, used with Keytruda, significantly reduced the risk of melanoma recurrence in a Phase 3 trial.

An experimental personalized cancer vaccine from Merck and Moderna has cleared a major clinical milestone, sending Moderna’s stock soaring approximately 177% following positive results from the therapy’s first Pha...


Read full story